KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer-Reference-Cited by-同舟云学术

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

Published:2019-04 Issue:10 Volume:15 Page:1057-1066
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Kato Ken¹,Shah Manish A²,Enzinger Peter³,Bennouna Jaafar⁴,Shen Lin⁵,Adenis Antoine⁶,Sun Jong-Mu⁷,Cho Byoung Chul⁸,Özgüroğlu Mustafa⁹,Kojima Takashi¹⁰,Kostorov Vladimir¹¹,Hierro Cinta¹²,Zhu Ying¹³,McLean Lee Anne¹³,Shah Sukrut¹³,Doi Toshihiko¹⁰

Affiliation:

1. National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

2. Weill Cornell Medical College, New York Presbyterian Hospital, 1305 York Avenue, Room Y1247, New York, NY 10065, USA

3. Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215-5450, USA

4. University Hospital of Nantes, Digestive Oncology, 1 Place Alexis Ricordeau, Nantes, 44000, France

5. Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian District, Beijing, 100142, PR China

6. Institut du Cancer de Montpellier, 208 Avenue des Apothicaries, Montpellier, 34298, France

7. Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Seoul, Republic of Korea

8. Severance Hospital, Yonsei University Health System, 50-1 Yonsei-ro, Seoul, Republic of Korea

9. Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Koca Mustafa Paşa Mahallesi, Cerrahpaşa Caddesi No. 53, Istanbul, 34096, Turkey

10. National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan

11. Leningrad Regional Oncology Dispensary, Ulitsa Savushkina, 126, Saint Petersburg, 197374, Russian Federation

12. Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), 119-129 Pg vall d'Hebron, Barcelona, 08035, Spain

13. Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA

Abstract

Background: Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. Aim: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry & ID: ClinicalTrials.gov : NCT03189719.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2018-0609

Reference33 articles.

1. WHO. GLOBOCAN 2012 estimated cancer incidence, mortality and prevalence worldwide. http://globocan.iarc.fr/Default.aspx.

2. The incidence and mortality of esophageal cancer and its relationship with development in the world

3. Cancer statistics, 2018

4. National Cancer Institute SEER. Previous version: SEER cancer statistics review, 1975–2011. https://seer.cancer.gov/archive/csr/1975_2011/.

5. Oesophageal carcinoma

Cited by 126 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Evolving Landscape of Neoadjuvant Immunotherapy in Gastroesophageal Cancer;Cancers;2024-01-09

2. Exacerbated prognostic impact of multiple intramural metastasis versus single intramural metastasis of thoracic esophageal squamous cell carcinoma: evidence from an Uzbekistan cohort;Surgery Today;2024-01-09

3. Sitravatinib combined with PD-1 blockade enhances cytotoxic T-cell infiltration by M2 to M1 tumor macrophage repolarization in esophageal adenocarcinoma;Carcinogenesis;2023-11-29

4. High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy;Journal for ImmunoTherapy of Cancer;2023-11